Ocugenix is developing treatments for eye diseases involving abnormal blood-vessel growth, inflammation and fibrosis. Built on University of Pittsburgh wound-healing research, its approach activates CXCR3 signaling to address these connected processes. Programs include wet age-related macular degeneration, geographic atrophy, proliferative diabetic retinopathy and dry eye disease. [1]
Founded by Sean McDonald, Alan Wells, Cecelia Yates and Ian Conner, Ocugenix has advanced its investigational programs through early clinical studies, including Phase IIa work, while preparing its dry-eye program for clinical development. [2] [3] [4]